# PHVS catalysts: Pharvaris N.V. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/phvs/catalysts

> Pharvaris N.V. (PHVS) has 3 upcoming catalysts. The next is the deucrictibant topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PHVS?

Pharvaris N.V. (PHVS) has 3 upcoming catalysts. The next is the deucrictibant topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Topline data from part 1 of CREAATE (NCT07266805) expected in 1Q2027." [Calendar and source filings](https://sec-api.dev/companies/phvs/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-456847, https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/phvs/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Pharvaris N.V. |
| Ticker | PHVS (Nasdaq) |
| SEC CIK | 1830487 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/phvs |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2021 | [Deucrictibant trial start](https://sec-api.dev/pdufa/deucrictibant) | PHVS | HAE in December 2022 | completed | "We commenced our RAPIDe-1 Phase 2 clinical trial of deucrictibant in February 2021 and reported topline Phase 2 data for the on-demand treatment of attacks in people with HAE in December 2022." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_2.htm)) |
| Dec 2022 | [Deucrictibant topline data readout](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | completed, positive | "In December 2022, we announced positive top-line data from RAPIDe-1, a Phase 2, double-blind, placebo-controlled, randomized, crossover, dose-ranging study of deucrictibant IR capsule for the on-demand treatment of HAE type 1 and type 2 (HAE-1/2) attacks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm)) |
| Dec 2022 | [PHVS416 trial start](https://sec-api.dev/pdufa/phvs416) | PHVS |  | completed | "We commenced our RAPIDe-1 Phase 2 clinical trial of PHVS416 in February 2021 and reported topline Phase 2 data for the acute treatment of patients with HAE attacks in December 2022." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525163778/d932470d424b5.htm)) |
| Dec 2023 | [Deucrictibant trial start](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | completed | "We commenced this CHAPTER-1 Phase 2 clinical trial in 2021 using twice-daily dosing of the deucrictibant immediate-release capsules as a proof-of-concept and announced positive topline data in December 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_2.htm)) |
| Dec 2023 | [Deucrictibant topline data readout](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | completed, positive | "A Phase 2 placebo-controlled trial evaluating the efficacy and the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and 2 (CHAPTER-1) commenced in 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023, demonstrating the clinical efficacy and tolerability of deucrictibant." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_2.htm)) |
| Mar 2024 | [Deucrictibant trial start](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | completed | "Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm)) |
| late 2024 | [Deucrictibant trial start](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE by year-end 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024126327/phvs-ex99_1.htm)) |
| Dec 2024 | [Deucrictibant trial start](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | completed | "In December 2024, we initiated CHAPTER-3, a global, pivotal, randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm)) |
| Oct 2025 | [Deucrictibant trial start](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | completed | "In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)) |
| Q4 2025 | [Deucrictibant topline data readout](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "Pharvaris expects to announce top-line data in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525276005/phvs-ex99_1.htm)) |
| 1H 2026 | [Deucrictibant NDA/BLA submission](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526266666/phvs-ex99_4.htm)) |
| Q1 2026 | [Deucrictibant topline data readout](https://sec-api.dev/pdufa/deucrictibant) | PHVS | HAE attacks | scheduled | "Topline data from RAPIDe-3 is anticipated in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025084094/phvs-ex99_4.htm)) |
| Q3 2026 | [Deucrictibant topline data readout](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm)) |
| September 30, 2026 | [Pharvaris N.V. topline data readout](https://sec-api.dev/companies/phvs/catalysts) | PHVS |  | scheduled | "We expect to report topline data from this study by September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_2.htm)) |
| Q1 2027 | [Deucrictibant topline data readout](https://sec-api.dev/pdufa/deucrictibant) | PHVS | AAE-C1INH attacks | scheduled | "Topline data from part 1 of CREAATE (NCT07266805) expected in 1Q2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)) |
| 1H 2027 | [Deucrictibant NDA/BLA submission](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "We plan to submit an NDA for deucrictibant XR for the prevention of AE-BK attacks with the FDA in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)) |
| April 23, 2027 | [Deucrictibant PDUFA date](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)) |

## Drugs

- [Deucrictibant](https://sec-api.dev/pdufa/deucrictibant): aae-c1inh attacks, hae attacks, hae in december 2022
- [PHVS416](https://sec-api.dev/pdufa/phvs416): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/phvs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PHVS catalysts: Pharvaris N.V. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/phvs/catalysts

```bibtex
@misc{secapidev_companies_phvs_catalysts_20261116,
  title        = {PHVS catalysts: Pharvaris N.V. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/phvs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_phvs_catalysts_20261116","title":"PHVS catalysts: Pharvaris N.V. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/phvs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
